Translation: Finding sense in the context (2024)

When a ribosome is translating a molecule of messenger RNA (mRNA) to produce a protein, it stops when it encounters a triplet of nucleotides called a termination codon. Ribosomes recognize three different termination codons – UAG, UAA and UGA – but a genetic event called a nonsense mutation can change a codon that normally codes for an amino acid – such as UAU, which codes for tyrosine – into a codon that stops translation prematurely. This results in the production of a truncated protein that does not work properly. Indeed, nonsense mutations cause a wide range of genetic conditions in millions of people worldwide, representing as much as 11% of all disease-associated gene lesions (Mort et al., 2008).

One way to treat the conditions caused by nonsense mutations would be to target premature termination events (Lee and Dougherty, 2012; Keeling et al., 2014; Dabrowski et al., 2018). For example, small molecules such as aminoglycoside antibiotics can help ribosomes to ignore premature termination codons and produce some full-length working proteins, an event called ‘readthrough’. However, aminoglycosides may also help ribosomes to readthrough normal termination codons: this can produce longer-than-normal proteins that are harmful to cells.

Now, in eLife, Jamie Wangen and Rachel Green of Johns Hopkins University School of Medicine report new insights into the way that aminoglycosides suppress termination (Wangen and Green, 2020; Figure 1). To do so, they harnessed and adapted a method known as ribosomal profiling, which reveals all the mRNAs that are being translated at a given time in a cell. In particular, the technique can highlight where ribosomes start and stop translation (Figure 1).

First, Wangen and Green used ribosomal profiling to examine translation in human cells treated with the aminoglycoside G418. Cells that were exposed to G418 had fewer ribosomes attached to normal termination codons; more ribosomes, however, were bound to regions of mRNA downstream of these termination codons, indicating that readthrough had occurred (thus allowing ribosomes to continue to translate past the normal stop points). Together, these findings indicate that G418 helps ribosomes to bypass normal termination codons; other results also suggest that the drug broadly interferes with other steps of the translation process.

Second, ribosomal profiling was used to examine how the mRNA sequence around a termination codon influences readthrough: this approach confirmed and built upon results from a number of previous studies (Martin, 1994; Phillips-Jones et al., 1995; Manuvakhova et al., 2000; Cassan and Rousset, 2001; Namy et al., 2001). Whether the termination codon was UAG, UAA or UGA, the identity of the two nucleotides directly downstream of these sequences had the greatest impact on readthrough. In addition, if neighboring sequences were rich in adenine and uridine, readthrough became more frequent.

Third, in cells treated with G418, readthrough events happened less often for normal termination codons than they did for other, downstream termination codons (which are not normally read by ribosomes). This indicates that normal termination codons have evolved safeguards to protect themselves from readthrough. It also suggests it may be possible to target premature termination codons – which may be more vulnerable since they have not been through a similar selection process – without disrupting accurate termination events.

Fourth, Wangen and Green explored the biological consequences of G418 inducing readthrough of normal termination codons. The majority of mRNAs were only modestly affected, but certain genes were more sensitive to the translation events induced by the drug – namely, the histone, selenoprotein, and S-adenosylmethionine decarboxylase genes.

Multiple genetic and biochemical studies have investigated the mechanisms of nonsense suppression, but only for a few transcripts at a time. The work by Wangen and Green, on the other hand, highlights how ribosomal profiling can confirm these findings at a genomic level. This confirmation is important when considering how to suppress premature termination codons for therapeutic purposes. By adapting ribosomal profiling to explore translation termination, Wangen and Green have created an important tool to investigate nonsense suppression in normal circ*mstances and under the influence of aminoglycosides. The method could also be used to examine how other readthrough agents act on premature and normal termination codons, as well as on global gene expression. This work could potentially helptoidentify new, safe and effective molecules that could be developed for clinical use.

1. 1. Cassan M
   2. Rousset JP

   (2001) UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals

   BMC Molecular Biology 2:3.

   https://doi.org/10.1186/1471-2199-2-3

   See Also

   From RNA to ProteinThe Role of RNA in Protein SynthesisRibosome reactivates transcription by physically pushing RNA polymerase out of transcription arrestDNA Transcription

   • PubMed
   • Google Scholar
2. 1. Dabrowski M
   2. Bukowy-Bieryllo Z
   3. Zietkiewicz E

   (2018) Advances in therapeutic use of a drug-stimulated translational readthrough of premature termination codons

   Molecular Medicine 24:25.

   https://doi.org/10.1186/s10020-018-0024-7

   • PubMed
   • Google Scholar
3. 1. Keeling KM
   2. Xue X
   3. Gunn G
   4. Bedwell DM

   (2014) Therapeutics based on stop codon readthrough

   Annual Review of Genomics and Human Genetics 15:371–394.

   https://doi.org/10.1146/annurev-genom-091212-153527

   • PubMed
   • Google Scholar
4. 1. Lee HL
   2. Dougherty JP

   (2012) Pharmaceutical therapies to recode nonsense mutations in inherited diseases

   Pharmacology & Therapeutics 136:227–266.

   https://doi.org/10.1016/j.pharmthera.2012.07.007

   • PubMed
   • Google Scholar
5. 1. Manuvakhova M
   2. Keeling K
   3. Bedwell DM

   (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system

   RNA 6:1044–1055.

   https://doi.org/10.1017/S1355838200000716

   • PubMed
   • Google Scholar
6. 1. Martin R

   (1994) On the relationship between preferred termination codon contexts and nonsense suppression in human cells

   Nucleic Acids Research 22:15–19.

   https://doi.org/10.1093/nar/22.1.15

   See Also

   Transcription and translation: 5 differences to know about

   • PubMed
   • Google Scholar
7. 1. Mort M
   2. Ivanov D
   3. Cooper DN
   4. Chuzhanova NA

   (2008) A meta-analysis of nonsense mutations causing human genetic disease

   Human Mutation 29:1037–1047.

   https://doi.org/10.1002/humu.20763

   • PubMed
   • Google Scholar
8. 1. Namy O
   2. Hatin I
   3. Rousset JP

   (2001) Impact of the six nucleotides downstream of the stop codon on translation termination

   EMBO Reports 2:787–793.

   https://doi.org/10.1093/embo-reports/kve176

   • PubMed
   • Google Scholar
9. 1. Phillips-Jones MK
   2. Hill LS
   3. Atkinson J
   4. Martin R

   (1995) Context effects on misreading and suppression at UAG codons in human cells

   Molecular and Cellular Biology 15:6593–6600.

   https://doi.org/10.1128/MCB.15.12.6593

   • PubMed
   • Google Scholar
10. 1. Wangen JR
    2. Green R

    (2020) Stop codon context influences genome-wide stimulation of termination codon readthrough by aminoglycosides

    eLife 9:e52611.

    https://doi.org/10.7554/eLife.52611

    • PubMed
    • Google Scholar

Author details

1. Kim M Keeling

   Kim M Keeling is in the Department of Biochemistry and Molecular Genetics and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, United States

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0003-0471-5858

2. David M Bedwell

   David M Bedwell is in the Department of Biochemistry and Molecular Genetics and the Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, United States

   For correspondence

   [email protected]

   Competing interests

   No competing interests declared

   "This ORCID iD identifies the author of this article:" 0000-0002-6605-818X

• 1,065

  views

• 117

  downloads

• 1

  citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.